Pink medicine with capecitabine for HER2-positive breast cancer that has spread to the brain
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two anti-cancer drugs for people with HER2-positive breast cancer that has spread to the brain and has not responded to a prior antibody-drug conjugate treatment. The goal is to see if this combination can shrink or control brain metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your breast cancer is HER2-positive and has spread to the brain, with at least one measureable brain lesion on an MRI.
- You have received fam-trastuzumab deruxtecan-nxki or A1811 for active brain metastases, and it has stopped working, but you have not had radiation therapy for these brain lesions.
- You have not taken capecitabine or pyrotinib before, or if you have, it was in the past as early-stage treatment and you've been off it for at least 6 months without your cancer returning.
- You are well enough to be up and about for at least part of the day (ECOG performance status of 0-2).
- Your vital organs (like blood, liver, kidneys, heart) are functioning within acceptable limits, as shown by recent lab tests and heart scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
This trial tests two new drugs, SHR-A1811 and THPy, for women with HER2-positive advanced breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and improve outcomes for patients who have not yet had systemic treatment for advanced disease.
This trial studies a combination of two oral drugs, neratinib and capecitabine, for people with HER2-positive stomach, esophageal, or gastroesophageal junction cancer that has spread to the brain. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests a new combination of targeted drugs for HER2-positive breast cancer that has spread to the brain. You might be able to join if you have brain metastases and are either newly diagnosed or have had prior brain radiation.
This trial tests a combination of two oral medications, capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy), for people with HER2-positive breast cancer that has spread and has already been treated with an antibody-drug conjugate (ADC). The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Hear when a new Metastatic Breast Cancer in the Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.